Portal de Periódicos da CAPES

The present and future disease burden of hepatitis C virus ( HCV ) infections with today's treatment paradigm – volume 2

2015; Wiley; Volume: 22; Issue: s1 Linguagem: Inglês

10.1111/jvh.12351

1365-2893

Angelos Hatzakis, Vladimir Chulanov, Adrían Gadano, Colm Bergin, Ziv Ben‐Ari, Joël Mossong, Ivan Schréter, Oidov Baatarkhuu, Subrat Kumar Acharya, Inka Aho, Anil C. Anand, Monique Andersson, Vic Arendt, Perttu Arkkila, Kieron Barclay, Fernando Bessone, Sarah Blach, Н. П. Блохина, Cheryl Brunton, G. Choudhuri, L. Cisneros, Esther Croes, Dahgwahdorj Yagaanbuyant, Olav Dalgård, Jorge Daruich, Naranjargal Dashdorj, D. Davaadorj, Robert J. de Knegt, M. de Vree, Chris Estes, Robert Flisiak, Edward Gane, E. Gower, Waldemar Halota, C. R. Henderson, Patrick Hoffmann, John Hornell, D. Houlihan, S. Hrušovský, Peter Jarčuška, David Kershenobich, K. Kostrzewska, Pavol Kristián, Moshe Leshno, Yoav Lurie, Adam Mahomed, N. Mamonova, Nahúm Méndez‐Sánchez, Suzanne Norris, E. Nurmukhametova, Pagbajabyn Nymadawa, Marián Oltman, Janchiv Oyunbileg, Ts. Oyunsuren, George Papatheodoridis, Nikolay Pimenov, Nishi Prabdial‐Sing, Maria Prins, Sarah Radke, Aza Rakhmanova, Kathryn Razavi‐Shearer, H. W. Reesink, Ezequiel Ridruejo, Rifaat Safadi, Olga Sagalova, J.F. Sánchez-Ávila, Ruvjir Sanduijav, V A Saraswat, Carole Seguin‐Devaux, Samir R. Shah, I V Shestakova, A. Shevaldin, Oren Shibolet, M. O. Silva, С. С. Соколов, Mark Sonderup, Kyriakos Souliotis, C. Wendy Spearman, Thérèse Staub, Catherine Stedman, Е.А. Strebkova, Daniel Struck, Vana Sypsa, Krzysztof Tomasiewicz, L. Undram, Adriaan J. van der Meer, Daniela van Santen, Irene Veldhuijzen, F. G. Villamil, Sophie B. Willemse, Eli Zuckerman, Freke Zuure, P. Puri, Homie Razavi,

Hepatitis B Virus Studies

Morbidity and mortality attributable to chronic hepatitis C virus (HCV) infection are increasing in many countries as the infected population ages. Models were developed for 15 countries to quantify and characterize the viremic population, as well as estimate the number of new infections and HCV related deaths from 2013 to 2030. Expert consensus was used to determine current treatment levels and outcomes in each country. In most countries, viremic prevalence has already peaked. In every country studied, prevalence begins to decline before 2030, when current treatment levels were held constant. In contrast, cases of advanced liver disease and liver related deaths will continue to increase through 2030 in most countries. The current treatment paradigm is inadequate if large reductions in HCV related morbidity and mortality are to be achieved.